Health Care

News Release | MASSPIRG | Public Health, Consumer Protection, Health Care

Some Good, Some Bad in Obama Executive Order on Protecting Antibiotics

New executive order on antibiotics takes several important steps necessary to control the spread of antibiotic-resistant bacteria, it misses the opportunity to call for critical reforms in the agricultural sector that are essential to protect public health. 

News Release | MASSPIRG Education Fund | Health Care

Group Calls on FDA to Protect Public Health by Regulating Antibiotic Use at Factory Farms

As outlined in our new report entitled Weak Medicine:  Why the FDA's New Guidelines Are Inadequate To Curb Antibiotic Resistance and Protect Public Health.  Guidelines issued by FDA last year lack the restrictions necessary to fully combat the increase in antibiotic-resistant bacteria documented by world health experts.

Report | MASSPIRG Education Fund | Health Care

Weak Medicine

 As outlined in our new report, Weak Medicine:  Why the FDA's New Guidelines Are Inadequate To Curb Antibiotic Resistance and Protect Public Health. Guidelines issued by the FDA last year lack the restrictions necessary to fully combat the increase in antibiotic-resistant bacteria documents by world health experts.

News Release | MASSPIRG and Community Catalyst | Public Health, Consumer Protection, Health Care

Twenty Top Generic Drugs Delayed by Industry Payoffs

Bay Staters with cancer, heart disease, epilepsy and other conditions have been forced to pay an average of 10 times more than necessary for at least 20 blockbuster drugs, according to a report released today by MASSPIRG and Community Catalyst.

Report | MASSPIRG and Community Catalyst | Public Health, Consumer Protection, Health Care

Top Twenty Pay-for-Delay Drugs

Too often, consumers are forced to shoulder a heavy financial burden, or even go without needed medicine, due to the high cost of brand-name drugs. Our research indicates that one significant cause is the practice called “pay for delay,” which inflates the drug prices paid by tens of millions of Americans.

News Release | MASSPIRG | Consumer Protection, Health Care

Big Pharma’s Pay-for-Delay Deals Take a Hit

Following Supreme Court decision, MASSPIRG calls for Congress to stop all drug companies from paying off generic competition.

2011-12 Legislative Scorecard

At the end of each 2-year legislative session, MASSPIRG grades state legislators' votes on key public interest issues.

Issue | Health Care

Fighting The High Cost Of Rx Drugs

Brand-name drug companies have been paying off generic drug makers to delay competition and keep prices high. This widespread pay-for-delay scheme needs to be put to an end. 

Report | MASSPIRG | Public Health, Health Care

Prescription for Danger

The contaminated drug that caused last fall’s fungal meningitis outbreak and killed 55 people is just the tip of the iceberg of an industry-wide problem.

A New Direction In Driving Trends

After a 60 year boom, driving is on the decline in the U.S. and no likely scenario shows it returning to previous levels of growth. 

Pages

Subscribe to RSS - Health Care

You Can Help

Your donation supports MASSPIRG's work to stand up for consumers on the issues that matter, especially when powerful interests are blocking progress.

Consumer Alerts

Join our network and stay up to date on our campaigns, get important consumer updates and take action on critical issues.
Optional Member Code